{"disease":{"id":"ebola","name":"ebola"},"drugs":{"marketed":[{"drug_id":"atoltivimab","indication_name":"Ebola virus disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inmazeb","generic_name":"ATOLTIVIMAB","company_name":"Regeneron","drug_phase":"marketed","molecular_target":"Low affinity immunoglobulin gamma Fc region receptor III-A","drug_class":"","quality_score":59,"revenue":"76","mechanism":"Inmazeb works by binding to the Ebola virus, preventing it from interacting with host cells and thereby reducing the severity of the disease."},{"drug_id":"odesivimab","indication_name":"Ebola virus disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inmazeb","generic_name":"ODESIVIMAB","company_name":"Regeneron","drug_phase":"marketed","molecular_target":"Low affinity immunoglobulin gamma Fc region receptor III-A","drug_class":"","quality_score":55,"revenue":"76","mechanism":"Inmazeb works by binding to the Ebola virus, preventing it from interacting with host cells."},{"drug_id":"maftivimab","indication_name":"Ebola virus disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inmazeb","generic_name":"MAFTIVIMAB","company_name":"Regeneron","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":55,"revenue":"76","mechanism":"Inmazeb works by binding to and neutralizing the Ebola virus."},{"drug_id":"inmazeb","indication_name":"Ebola virus disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Inmazeb","company_name":"ANRS, Emerging Infectious Diseases","drug_phase":"marketed","molecular_target":"Low affinity immunoglobulin gamma Fc region receptor III-A, Envelope glycoprotein","drug_class":"","quality_score":13,"revenue":null,"mechanism":null},{"drug_id":"ansuvimab-zykl","indication_name":"Ebola virus disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"EBANGA","generic_name":"ANSUVIMAB-ZYKL","company_name":"RIDGEBACK BIOTHERAPEUTICS","drug_phase":"marketed","molecular_target":"Envelope glycoprotein","drug_class":"","quality_score":19,"revenue":null,"mechanism":""},{"drug_id":"ansuvimab","indication_name":"Ebola virus disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ebov Mab114","generic_name":"ANSUVIMAB","company_name":"Ridgeback Biotherapeutics","drug_phase":"marketed","molecular_target":"","drug_class":"Zaire Ebolavirus Glycoprotein-directed Antibody","quality_score":35,"revenue":null,"mechanism":"Ansuvimab works by binding to the Ebola virus glycoprotein, preventing the virus from entering host cells."}],"pipeline":[],"offLabel":[],"totalMarketed":6,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04152486","title":"Effectiveness and Safety of a Heterologous, Two-dose Ebola Vaccine in the DRC","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":20426,"lead_sponsor_name":"London School of Hygiene and Tropical Medicine","has_results":false},{"nct_id":"NCT03098862","title":"PREVAIL VI: Identification of Host Genetic Factors Underlying Ebola Virus Disease Risk, Mortality, Long-term Sequelae, Viral RNA Persistence, Humoral Immunity, and Ebola Vaccine Response","phase":"","overall_status":"COMPLETED","enrollment_count":4830,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT02876328","title":"Partnership for Research on Ebola VACcinations","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":4789,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":true},{"nct_id":"NCT02431923","title":"Ebola Virus Disease Survivors: Clinical and Immunologic Follow-up","phase":"","overall_status":"COMPLETED","enrollment_count":4043,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT03072030","title":"International Multicenter Study of the Immunogenicity of Medicinal Product GamEvac-Combi","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":2000,"lead_sponsor_name":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","has_results":false},{"nct_id":"NCT02344407","title":"Partnership for Research on Ebola Vaccines in Liberia (PREVAIL)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":1500,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":true},{"nct_id":"NCT02503202","title":"Evaluation of the Safety and Immunogenicity of Three Consistency Lots and a High-Dose Lot of rVSV-ZEBOV-GP (V920 Ebola Vaccine) in Healthy Adults (V920-012)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1197,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT02564523","title":"Safety, Tolerability and Immunogenicity Study of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo in Healthy Adults, Children and Human Immunodeficiency Virus Positive (HIV+) Adults","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":1075,"lead_sponsor_name":"Janssen Vaccines & Prevention B.V.","has_results":true},{"nct_id":"NCT02509494","title":"Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1023,"lead_sponsor_name":"Janssen Vaccines & Prevention B.V.","has_results":true},{"nct_id":"NCT06093646","title":"Addressing Medium- to Long-term EBOLA Associated Psychological Distress and Psychosocial Problems in Central Uganda","phase":"NA","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"MRC/UVRI and LSHTM Uganda Research Unit","has_results":false},{"nct_id":"NCT04228783","title":"A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":974,"lead_sponsor_name":"Janssen Vaccines & Prevention B.V.","has_results":true},{"nct_id":"NCT04028349","title":"ZEBOVAC (Ebola Vaccine Trial, Ad26.ZEBOV/MVA-BN-Filo)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":800,"lead_sponsor_name":"MRC/UVRI and LSHTM Uganda Research Unit","has_results":false},{"nct_id":"NCT04409405","title":"Evaluation and Support to EVD Cured Patients and Their Contacts (Les Vainqueurs d'Ebola)","phase":"","overall_status":"COMPLETED","enrollment_count":787,"lead_sponsor_name":"Institut National de la Santé Et de la Recherche Médicale, France","has_results":false},{"nct_id":"NCT04815174","title":"Observational Study of the Clinico-biological Evolution and Standard of Care Offered to Patients With Ebola Virus Disease","phase":"","overall_status":"COMPLETED","enrollment_count":711,"lead_sponsor_name":"Alliance for International Medical Action","has_results":false},{"nct_id":"NCT04186000","title":"Study to Evaluate the Immunogenicity and Safety of a Heterologous Vaccine Regimen Against Ebola","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":699,"lead_sponsor_name":"Universiteit Antwerpen","has_results":false},{"nct_id":"NCT03719586","title":"Investigational Therapeutics for the Treatment of People With Ebola Virus Disease","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":681,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":true},{"nct_id":"NCT02661464","title":"Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":677,"lead_sponsor_name":"Janssen Vaccines & Prevention B.V.","has_results":true},{"nct_id":"NCT03820739","title":"EBOVAC-Salone Extension","phase":"","overall_status":"COMPLETED","enrollment_count":653,"lead_sponsor_name":"London School of Hygiene and Tropical Medicine","has_results":false},{"nct_id":"NCT02598388","title":"Safety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":578,"lead_sponsor_name":"Janssen Vaccines & Prevention B.V.","has_results":true},{"nct_id":"NCT02314923","title":"Placebo Controlled, Dose Response, Safety and Immunogenicity Study of Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-004)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":513,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT04235361","title":"Mobile Point of Care Diagnostic Testing for Ebola Virus Disease in DRC","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"University of Stirling","has_results":false},{"nct_id":"NCT03161366","title":"Providing Additional Information on the Safety and Effectiveness of an Ebola Vaccine","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":500,"lead_sponsor_name":"Epicentre","has_results":false},{"nct_id":"NCT02416453","title":"A Study to Assess Safety, Tolerability, and Immunogenicity of Three Heterologus 2-dose Regimens of the Candidate Prophylactic Vaccines for Ebola in Healthy Adults","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":423,"lead_sponsor_name":"Janssen Vaccines & Prevention B.V.","has_results":true},{"nct_id":"NCT06811129","title":"Long-Term Neurologic and Neurocognitive Sequelae Following Pediatric Ebola Virus in Liberia","phase":"","overall_status":"COMPLETED","enrollment_count":328,"lead_sponsor_name":"National Institute of Neurological Disorders and Stroke (NINDS)","has_results":false},{"nct_id":"NCT03031912","title":"African-Canadian Study of HIV-Infected Adults and a Vaccine for Ebola - ACHIV-Ebola","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":251,"lead_sponsor_name":"Canadian Immunization Research Network","has_results":true},{"nct_id":"NCT05494801","title":"Natural History, Disease Progression, and Long-Term Neurologic Sequelae of Ebola Virus Disease (EVD) Survivors in PREVAIL III","phase":"","overall_status":"COMPLETED","enrollment_count":203,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT05284097","title":"Ad26.ZEBOV, MVA-BN-Filo Vaccination in Children and Adults Previously Vaccinated With Control in the EBOVAC-Salone Study","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":133,"lead_sponsor_name":"London School of Hygiene and Tropical Medicine","has_results":false},{"nct_id":"NCT03140774","title":"Persistence of the Immune Response After Immunisation With Ebola Virus Vaccines","phase":"","overall_status":"COMPLETED","enrollment_count":126,"lead_sponsor_name":"University of Oxford","has_results":false},{"nct_id":"NCT06036602","title":"Monovalent Chimpanzee Adenoviral-Vectored Sudan Ebolavirus Vaccine in Healthy Adults","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":125,"lead_sponsor_name":"Albert B. Sabin Vaccine Institute","has_results":false},{"nct_id":"NCT05130398","title":"Safety and Immunogenicity of the rVSVΔG-ZEBOV-GP Ebola Virus Vaccine Candidate in Children Living in Lambaréné, Gabon","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":120,"lead_sponsor_name":"Centre de Recherche Médicale de Lambaréné","has_results":false},{"nct_id":"NCT03929757","title":"A Study of 2-dose Vaccination Regimen of Ad26.ZEBOV and MVA-BN-Filo in Infants","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":108,"lead_sponsor_name":"Janssen Vaccines & Prevention B.V.","has_results":true},{"nct_id":"NCT02240875","title":"A Study to Assess New Ebola Vaccines, cAd3-EBO Z and MVA-BN® Filo","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":91,"lead_sponsor_name":"University of Oxford","has_results":false},{"nct_id":"NCT02354404","title":"Clinical Trial of Ebola Vaccines cAd3-EBO, cAd3-EBOZ and MVA-EbolaZ in Healthy Adults in Uganda","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":90,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT02363322","title":"Putative Investigational Therapeutics in the Treatment of Patients With Known Ebola Infection","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":72,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":true},{"nct_id":"NCT02891980","title":"A Safety Trial to Test MVA-BN(R)-Filo and Ad26.ZEBOV Vaccines in Healthy Volunteers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":65,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT03583606","title":"A Trial to Evaluate the Safety and Systems Biology Response of Ebolavirus Zaire Vaccine (ChAd3-EBO-Z)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":61,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":true},{"nct_id":"NCT00646152","title":"Poly-ICLC to Prevent Respiratory Viral Infections A Safety Study","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":57,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT04711356","title":"Ad26.ZEBOV Booster in Children Previously Vaccinated With Ad26.ZEBOV and MVA-BN-Filo (EBOVAC Booster Study)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"London School of Hygiene and Tropical Medicine","has_results":true},{"nct_id":"NCT00374309","title":"Experimental Vaccine for Prevention of Ebola Virus Infection","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":48,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT04906629","title":"INO-4201 as Booster in Healthy VSV-ZEBOV Vaccinees","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":46,"lead_sponsor_name":"University of Geneva, Switzerland","has_results":false},{"nct_id":"NCT04250168","title":"Piloting Clinical Bacteriology in the Ebola Virus Disease Care Response","phase":"","overall_status":"TERMINATED","enrollment_count":43,"lead_sponsor_name":"Institute of Tropical Medicine, Belgium","has_results":false},{"nct_id":"NCT04041570","title":"Ebola Sudan Chimpanzee Adenovirus Vector Vaccine in Healthy Adults","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":true},{"nct_id":"NCT02269423","title":"Vaccine Treatment for Ebola Virus in Healthy Adults (V920-001)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":39,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT02280408","title":"Safety and Immunogenicity of Prime-Boost Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-002)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":39,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT02718469","title":"Trial to Evaluate Safety and Immunogenicity of an Ebola Zaire Vaccine in Healthy Adults","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":38,"lead_sponsor_name":"Auro Vaccines LLC","has_results":false},{"nct_id":"NCT02818582","title":"GS-5734 to Assess the Antiviral Activity, Longer-Term Clearance of Ebola Virus, and Safety in Male Ebola Survivors With Evidence of Ebola Virus Persistence in Semen","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":38,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":true},{"nct_id":"NCT02451891","title":"A Phase I Study to Assess Ebola Vaccines cAd3-EBO Z and MVA-EBO Z","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":38,"lead_sponsor_name":"University of Oxford","has_results":false},{"nct_id":"NCT05724472","title":"Evaluation of Safety and Immunogenicity of rVSVΔG-SEBOV-GP Vaccine in Adults With Good General Health","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":36,"lead_sponsor_name":"International AIDS Vaccine Initiative","has_results":false},{"nct_id":"NCT02495246","title":"A Study to Assess Ebola Vaccines ChAd3-EBO-Z and Ad26.ZEBOV","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":32,"lead_sponsor_name":"University of Oxford","has_results":false},{"nct_id":"NCT04723602","title":"Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":32,"lead_sponsor_name":"Albert B. Sabin Vaccine Institute","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}